Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care invited healthcare experts to discuss the challenges associated with managing and paying for newer and more expensive agents in oncology, during the Oncology Stakeholders Summit.

Basket and umbrella studies as well as adaptive enrichment design strategies represent novel approaches to testing targeted therapeutics in oncology, and a session at ASCO's annual meeting discussed the nuts and bolts of these design strategies.

Two posters summarized the safety of nivolumab in lung cancer and in glioblastoma, at the ASCO annual meeting.

A new study published in Neurology, has shown that long-term inflammation in older patients with diabetes can also hasten their cognitive decline.

Till Kalydeco was approved, cystic fibrosis patients primarily received only disease management support to extend their lives.

The widespread use of screening mammography increases the probability of detecting smaller cancers without a decline in the detection of large cancers.

To evaluate the current status of cancer mortality following the initiation of HP2020, CDC scientists evaluated population trends and made projections on cancer deaths based on race and gender.

The Attorney General of Massachussetts, Maura Healy, wants healthcare services in the state to pay increased attention to mental health benefits.

Heterogeneity in Medicaid coverage of the anti-viral agent sofosbuvir is rampant across the United States, with varying reimbursement criteria and lack of conformation to recommendations by professional infectious disease organizations.

Accelerated review of "me-too" products would increase market competition entailing a drug price competition, said experts at a panel discussion during a recent biotechnology meeting.

Researchers at the MD Anderson Cancer Center have developed a blood test that can detect very early stages of pancreatic cancer before disease progression.

NICE has updated and redesigned its guideline to support primary care physicians to recognize the signs and symptoms of 37 different cancers and refer people for the right tests faster.

A framework that primarily considers clinical benefit, toxicity, and cost of new treatments was released today by ASCO. A presscast complementing the release described the framework as a tool for providers to discuss value of new treatments with patients, compared with the standard of care.

A paper published in the British Medical Journal, authored by FDA staff, compares content from FDA's complete response letter for a rejected drug, with the subsequent press release by drug developers.

Glooko, a mobile support platform for diabetes care, helps fill the gaps created by the shortage of endocrinologists. Self-care is key to reducing the number of hypoglycemia incidents.

Combination therapy in diabetes care can offer benefits but might not be right for certain populations or at certain stages of care.

The House Energy and Commerce Committee is drafting language that will help create an in vitro center within the FDA to define risk categories for laboratory-developed tests (LDTs), and set timelines to accelerate the approval process for LDTs.

An initiative aimed at speeding the drug development process to ensure patients have faster access to innovative treatments, several provisions of the bill have received mixed reviews.

In the keynote presentation at Patient-Centered Diabetes Care 2015, Robert A. Gabbay, MD, PhD, discusses how new payment models can improve care in both type 1 and type 2 diabetes.

The study found that early palliative care consultations in hospitalized cancer patients significantly reduced the cost of hospital stays.

The report found a 6.5% increase in the compound annual growth rate during the 5-year period leading up to 2014.

BMS has submitted phase 3 results from the CheckMate-066 trial, comparing nivolumab with dacarbazine in treatment-naïve advanced melanoma patients.

A US appeals court has blocked Novartis from selling the first biosimilar to be approved in the United States.

While the 21st Century Cures Act that was recently approved is full of promise for healthcare innovation, experts warn against some of the Act's provisions.

Anju Nohria, MD, assistant professor, Harvard Medical School, spoke to Evidence-Based Oncology about some of the challenges clinicians face with monitoring cardiovascular risks in cancer patients.

The American Journal of Managed Care convened experts in health policy, from health plans, and from community oncology, to discuss OCM and other issues in oncology care during the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

To discuss patient-reported outcomes and their importance in patient-centered care, The American Journal of Managed Care convened a panel of healthcare experts to participate in the Oncology Stakeholders Summit, Spring 2015 Peer Exchange.

Much-anticipated trial results were presented on the third day of the annual meeting of the American Society of Clinical Oncology, held in Chicago. These included phase 3 results from the CheckMate 067 trial and a phase 2 study with elotuzumab.

While the clinical data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) created waves, a session on value had an equally significant impact as oncologists thronged to hear stakeholder voices define this, as yet abstract, concept of "value" in cancer care. The session brought together a patient representative, an oncologist, an ASCO representative, and a payer.

A late-breaking abstract session early on the second day of the annual meeting of the American Society of Clinical Oncology was reserved for the latest data from clinical trials evaluating the new immuno-oncology agents of the PD-1 inhibitor class.